You can buy or sell OSUR and other stocks, options, ETFs, and crypto commission-free!
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. Read More The OSUR segment develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices. The DNAG segment manufactures and sells specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.
52 Week High
52 Week Low
Simply Wall StMar 20
At US$11.56, Is OraSure Technologies, Inc. (NASDAQ:OSUR) Worth Looking At Closely?
OraSure Technologies, Inc. (NASDAQ:OSUR), which is in the medical equipment business, and is based in United States, received a lot of attention from a substantial price increase on the NASDAQGS over the last few months. With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. But what if there is still an opportunity to buy? Let’s examine OraSure Technologies’s valuation and outlook in more detail to determine if there’s...
Yahoo FinanceMar 15
OraSure Technologies (NASDAQ:OSUR) Shareholders Have Enjoyed A 54% Share Price Gain
By buying an index fund, investors can approximate the average market return. But if you buy good businesses at attractive prices, your portfolio returns could exceed the average market return. For example, OraSure Technologies, Inc. (NASDAQ:OSUR) shareholders have seen the share price rise 54% over three years, well in excess of the market return (38%, not including dividends). View our latest analysis for OraSure Technologies Scroll to continue with content Ad In his essay The Superinvestors of Graham-...
The Motley FoolMar 7
Why OraSure Stock Lost 16% in February
What happened Medical product specialist OraSure (NASDAQ:OSUR) trailed the market last month by shedding 16% compared to a 3% spike in the S&P 500, according to data provided by S&P Global Market Intelligence. The decline contributed to significant losses for shareholders recently, with the stock down nearly 40% in the past year. So what Investors reacted harshly to OraSure's fourth-quarter results, which in early February showed that sales fell 11% overall thanks to a drop off in its key genomics divis...
Expected May 1, After Hours